Skip to NavigationSkip to content

Andrew Sandham, executive chairman, Syntaxin

Published on: 20/10/09

Syntaxin, a biopharmaceutical company developing novel biologic drugs that control cell secretion, has appointed Andrew Sandham executive chairman.

This follows the resignation of chief exeuctive, Patrick Doyle, for personal reasons.  Mr Sandham has worked closely with Syntaxin since its formation in 2005, as chairman of the board.  A search has been initiated for the vacant chief executive position.


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches